CPC C07K 17/08 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 47/605 (2017.08); A61K 47/6845 (2017.08); A61P 27/02 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01)] | 43 Claims |
1. A method of treating an eye disorder, comprising:
administering three loading doses of an anti-VEGF antibody conjugate to a subject in need of treating an eye disorder at a first loading dose, wherein the eye disorder is wet age-related macular degeneration (wAMD),
wherein the anti-VEGF antibody conjugate comprises:
an antibody conjugate comprising a light chain and a heavy chain, wherein the heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and the light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14), and wherein the heavy chain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1 and the light chain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 2; and
a phosphorylcholine containing polymer covalently bonded to the heavy chain, wherein the polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers, and wherein the polymer has a molecular weight of between about 600,000 and about 1,000,000 Da
whereby the subject retains a therapeutic result of the anti-VEGF antibody conjugate therapy for at least 12 weeks after a final loading dose.
|